Update on Desensitization
- 2 Downloads
Purpose of review
Rapid drug desensitization (RDD) is a high-risk protocol that allows patients with hypersensitivity reactions to remain on first-line therapy for their underlying conditions through titration of dose increments and infusion rates. The aim of this paper is to review the most recent desensitization protocols available for drugs that are commonly used in clinical practice settings and to provide algorithms for their appropriate usage.
RDD protocols involve identification of phenotypes and endotypes during the initial reaction, risk stratification, skin testing, and specific biomarkers. Patients’ protocols are personalized and can increase life expectancy and quality of life.
The benefits of RDD largely outweigh the risks. All patients with hypersensitivity reactions should be evaluated for desensitization, to avoid alternatives treatments that may be less effective or intolerant patients presenting with SCARS (DRESS/SJS/TEN) are not candidates for desensitization since the mechanism of the reactions are poorly understood.
KeywordsDesensitization Chemotherapy Drug hypersensitivity reactions Monoclonal antibodies Antibiotics Biomarkers Progesterone
Compliance with ethical standards
Conflict of interest
Lucila Campos declares that she has no conflicts of interest. Sahar Hamadi declares that she has no conflicts of interest. Donna-Marie Lynch declares that she has no conflicts of interest. Kathleen Marquis declares that she has no conflicts of interest. Mariana Castells declares that she has no conflicts of interest
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.•• Castells MC. Drug allergy: phenotypes, endotypes, and biomarkers. J Allergy Clin Immunol Pract. 2017;5(3):626–7 This study classifies the different phenotypes and endotypes of drug hypersensitivity reactions, allowing the better understanding of the underlying mechanisms of those reactions to define the treatment algorithms and desensitization protocols.PubMedCrossRefPubMedCentralGoogle Scholar
- 22.Pyle RC, Butterfield JH, Volcheck GW, Podjasek JC, Rank MA, Li JT, et al. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction. J Allergy Clin Immunol Pract. 2014;2(1):52–8.PubMedCrossRefPubMedCentralGoogle Scholar
- 24.• Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract. 2016. This paper evaluates the efficacy and the cost effectiveness of desensitization and its impact on patient’s overall survival rates and quality of life.;4:497–504.PubMedCrossRefPubMedCentralGoogle Scholar
- 25.Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract. 2013;1(5):494–500.PubMedCrossRefPubMedCentralGoogle Scholar
- 33.• Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142(1):159–70 e2 This paper reviews hypersensitivity reactions to the main monoclonal antibodies used in clinical practice and desensitization protocols.PubMedCrossRefPubMedCentralGoogle Scholar